With shortstop Nick Madrigal due for a long absence with a fractured shoulder, the Mets could reunite with a fan favorite ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

New York Mets starter Sean Manaea is expected to begin the season on the injured list because of a right oblique strain.

They still view Iglesias as “not a fit” for their roster, according to a person familiar with the Mets’ thinking. That leaves ...

New York Mets infielder Nick Madrigal dislocated his left shoulder in the first inning of the club's split-squad contest ...

New York Mets infielder Nick Madrigal dislocated his non-throwing shoulder in a spring training game against the Washington ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Shares of Madrigal Pharmaceuticals ( MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

The Mets’ bench competition experienced some early upheaval on Sunday, when infielder Nick Madrigal dislocated his left ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...